 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- || EXN407 / Exonate, J&J
Trial completion: A Study to Evaluate the Safety and Tolerability of EXN407 (clinicaltrials.gov) - Jan 10, 2023
P1/2, N=48, Completed, Sponsor: Exonate Limited
Active, not recruiting --> Completed
- | EXN407 / Exonate, J&J
Enrollment closed, Trial primary completion date: A Study to Evaluate the Safety and Tolerability of EXN407 (clinicaltrials.gov) - Aug 4, 2022
P1/2, N=48, Active, not recruiting, Sponsor: Exonate Limited
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2022 --> Oct 2022
- | EXN407 / Exonate, J&J
Trial primary completion date: A Study to Evaluate the Safety and Tolerability of EXN407 (clinicaltrials.gov) - Aug 18, 2021
P1/2, N=48, Recruiting, Sponsor: Exonate Limited
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2022 --> Oct 2022 Trial primary completion date: Nov 2021 --> Mar 2022
- || EXN407 / Exonate, J&J
Enrollment open: A Study to Evaluate the Safety and Tolerability of EXN407 (clinicaltrials.gov) - Nov 26, 2020
P1/2, N=48, Recruiting, Sponsor: Exonate Limited
Trial primary completion date: Nov 2021 --> Mar 2022 Not yet recruiting --> Recruiting
- || EXN407 / Exonate, J&J
New P1/2 trial: A Study to Evaluate the Safety and Tolerability of EXN407 (clinicaltrials.gov) - Sep 24, 2020
P1/2, N=48, Not yet recruiting, Sponsor: Exonate Limited